A Study to Determine the Bioequivalence of Two Doses of Tafamidis

NCT ID: NCT04575116

Last Updated: 2021-03-08

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 23 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-09-17
• Study Completion Date: 2021-02-23

Brief Summary

Study to characterize the bioequivalence of a 12.2 mg free acid tablets compared to commercial supply (tafamidis meglumine soft gelatin 20 mg capsule) in healthy participants under fasted conditions.

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: NONE

Study Groups

Tafamidis Free acid tablet then tafamidis meglumine capsule

On Day 1 of each period, participants will receive a single dose of 1 of tafamidis formulations. Each period is separated by a washout of at least 16 days between administration of study drug.

Group Type: EXPERIMENTAL

Tafamidis free acid tablet

Intervention Type: DRUG

12.2 mg tafamidis free acid tablet

Tafamidis meglumine capsule

Intervention Type: DRUG

20 mg tafamidis meglumine soft gelatin capsule

Tafamidis meglumine capsule then Tafamidis Free acid tablet

On Day 1 of each period, participants will receive a single dose of 1 of tafamidis formulations. Each period is separated by a washout of at least 16 days between administration of study drug.

Group Type: EXPERIMENTAL

Tafamidis free acid tablet

Intervention Type: DRUG

12.2 mg tafamidis free acid tablet

Tafamidis meglumine capsule

Intervention Type: DRUG

20 mg tafamidis meglumine soft gelatin capsule

Interventions

Tafamidis free acid tablet

12.2 mg tafamidis free acid tablet

Intervention Type: DRUG

Tafamidis meglumine capsule

20 mg tafamidis meglumine soft gelatin capsule

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Male and female participants must be 18 to 55 years of age, inclusive, at the time of signing the ICD.

2. Healthy female participants of nonchildbearing potential and/or male participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiovascular tests.

3. Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures.

4. BMI of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs).

5. Capable of giving signed informed consent and compliance with study requirements and restrictions

Exclusion Criteria

Medical Conditions:

1. Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).

2. Any condition possibly affecting drug absorption (eg, gastrectomy).

3. History of HIV infection, hepatitis B, or hepatitis C; positive testing for HIV, HBsAg, HBcAb, or HCVAb. Hepatitis B vaccination is allowed.

4. Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.

Prior/Concomitant Therapy:

5. Use of prescription or nonprescription drugs and dietary and herbal supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study intervention.

Prior/Concurrent Clinical Study Experience:

6. Previous administration with an investigational drug within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer).

Diagnostic Assessments:

7. A positive urine drug test.

8. Screening supine BP ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic), following at least 5 minutes of supine rest. If BP is ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic), the BP should be repeated 2 more times and the average of the 3 BP values should be used to determine the participant's eligibility.

9. Baseline 12 lead ECG that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results (eg, baseline QTc interval >450 msec, complete LBBB, signs of an acute or indeterminate age myocardial infarction, ST T interval changes suggestive of myocardial ischemia, second or third degree AV block, or serious bradyarrhythmias or tachyarrhythmias). If the baseline uncorrected QT interval is >450 msec, this interval should be rate corrected using the Fridericia method and the resulting QTcF should be used for decision making and reporting. If QTc exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated 2 more times and the average of the 3 QTc or QRS values should be used to determine the participant's eligibility. Computer interpreted ECGs should be overread by a physician experienced in reading ECGs before excluding participants.

10. Participants with ANY of the following abnormalities in clinical laboratory tests at screening, as assessed by the study specific laboratory and confirmed by a single repeat test, if deemed necessary:

• AST or ALT level greater than or equal to 1.5 × upper limit of normal (ULN);
• Total bilirubin level greater than or equal 1.5 × ULN; participants with a history of Gilbert's syndrome may have direct bilirubin measured and would be eligible for this study provided the direct bilirubin level is greater than or equal ULN.

Other Exclusions:

11. History of alcohol abuse or binge drinking and/or any other illicit drug use or dependence within 6 months of Screening. Binge drinking is defined as a pattern of 5 (male) and 4 (female) or more alcoholic drinks in about 2 hours. As a general rule, alcohol intake should not exceed 14 units per week (1 unit = 8 ounces (240 mL) beer, 1 ounce (30 mL) of 40% spirit or 3 ounces (90 mL) of wine).

12. Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 60 days prior to dosing.

13. History of sensitivity to heparin or heparin induced thrombocytopenia.

14. Unwilling or unable to comply with the criteria in the Lifestyle Considerations section of this protocol.

15. Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.

16. Use of tobacco or nicotine-containing products in excess of the equivalent of 5 cigarettes per day.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Pfizer

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

New Haven Clinical Research Unit

New Haven, Connecticut, United States

Countries

United States

Related Links

https://pmiform.com/clinical-trial-info-request?StudyID=B3461095

To obtain contact information for a study center near you, click here.

Other Identifiers

Tafamidis

Identifier Type: OTHER

Identifier Source: secondary_id

B3461095

Identifier Type: -

Identifier Source: org_study_id